TargetMol

PHA-767491

Product Code:
 
TAR-T6206
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6206-2mg2mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6206-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6206-5mg5mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6206-10mg10mg£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6206-25mg25mg£179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6206-50mg50mg£260.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6206-100mg100mg£413.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
CAS:
845714-00-3
Formula:
C12H11N3O
Molecular Weight:
213.24
Pathway:
PI3K/Akt/mTOR signaling; GPCR/G Protein; Stem Cells; Cell Cycle/Checkpoint
Purity:
0.9942
SMILES:
O=C1NCCc2[nH]c(cc12)-c1ccncc1
Target:
cholecystokinin; GSK-3; CDK

Documents

References

Yecies D, et al. Blood, 2010, 115(16), 3304-3313. Montagnoli A, et al. Nat Chem Biol, 2008, 4(6), 357-365. Yu Z, Deng P, Chen Y, et al. Inhibition of the PLK1?Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. Advanced Science. 2021: 2100759. Natoni A, et al. Mol Cancer Ther, 2011, 10(9), 1624-1634. Shan X, Jiang R, Gou D, et al.Identification of a diketopiperazine?based O?GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition.The FEBS Journal.2023